BioCentury
ARTICLE | Clinical News

NCX 1015: Began Phase I trial

January 2, 2001 8:00 AM UTC

NicOx S.A. (NM:Nicox), Sophia-Antipolis, France Product: NCX 1015 Business: Autoimmune/Inflammation Therapeutic category: Steroid, Nitric oxide Target: Immune cells Description: Nitric oxide (NO)-rel...